Kinases are important drug discovery targets for a wide variety of therapeutic indications; consequently, the measurement of kinase activity remains a common high-throughput screening (HTS) application. Recently, enzyme-coupled luciferase-kinase (LK) format assays have been introduced. This format measures luminescence resulting from metabolism of adenosine triphosphate (ATP) via a luciferin/luciferase-coupled reaction. In the research presented here, 1536-well format time-resolved fluorescence resonance energy transfer (TR-FRET) and LK assays were created to identify novel Rho-associated kinase II (ROCK-II) inhibitors. HTS campaigns for both assays were conducted in this miniaturized format. It was found that both assays were able to consistently reproduce the expected pharmacology of inhibitors known to be specific to ROCK-II (fasudil IC50: 283 ± 27 nM and 336 ± 54 nM for TR-FRET and LK assays, respectively; Y-27632 IC50: 133 ± 7.8 nM and 150 ± 22 nM for TR-FRET and LK assays, respectively). In addition, both assays proved robust for HTS efforts, demonstrating excellent plate Z′ values during the HTS campaign (0.84 ± 0.03; 0.72 ± 0.05 for LK and TR-FRET campaigns, respectively). Both formats identified scaffolds of known and novel ROCK-II inhibitors with similar sensitivity. A comparison of the performance of these 2 assay formats in an HTS campaign was enabled by the existence of a subset of 25,000 compounds found in both our institutional and the Molecular Library Screening Center Network screening files. Analysis of the HTS campaign results based on this subset of common compounds showed that both formats had comparable total hit rates, hit distributions, amount of hit clusters, and format-specific artifact. It can be concluded that both assay formats are suitable for the discovery of ROCK-II inhibitors, and the choice of assay format depends on reagents and/or screening technology available. (Journal of Biomolecular Screening 2008:17-28) 
INTRODUCTION
C ONSISTING OF 518 KINASES, 1 the human kinome remains a rich source of targets for drug discovery. Largely due to this popularity, a variety of kinase activity detection kits are available for high-throughput screening (HTS) applications. [2] [3] [4] [5] [6] [7] Among the many detection formats, time-resolved fluorescence resonance energy transfer (TR-FRET) methods are perhaps the most popular. Typically, this format employs a lanthanide-labeled antibody that recognizes only the phosphorylated protein or peptide product. As would be expected from an antibody-based detection technology, the TR-FRET format offers exquisite selectivity and sensitivity for HTS kinase applications. 8, 9 Recently, an enzyme-coupled luciferase-kinase (LK) assay was introduced. 10 Its detection principle exploits the oxidation of luciferin by luciferase to quantify kinase activity. Although marketed in kit form by multiple vendors, 11, 12 the mechanism of signal development is similar for each kit: once the luciferase/ luciferin components are added to a kinase reaction, residual adenosine triphosphate (ATP) is metabolized by luciferase, resulting in the formation of oxyluciferin and consequent release of measurable luminescence. The amount of luminescence generated is proportional to the amount of ATP present in the assay buffer and assumed to be inversely dependent on the amount of phosphorylated kinase cosubstrate.
Based on preliminary considerations, the LK format has beneficial features that make it competitive to the TR-FRET format. First, as with several TR-FRET formats, the LK format is homogeneous and therefore amenable to 1536-well miniaturization. In contrast, the simplicity of the LK format avoids the antibody preparation and multiparameter donor/acceptor optimization effort associated with TR-FRET assay development. The LK assay also requires unsophisticated instrumentation (i.e., a luminometer) to measure the luciferase activity. Finally, due to the ease of its production, the lower cost of the luciferase substrate may make the LK assay attractive for economic reasons.
Rho-associated coiled-coil-containing protein serine/threonine kinase II (ROCK-II) is a serine/threonine kinase involved in the regulation of smooth muscle contraction and cytoskeletal reorganization of nonmuscle cells. 13 Small-molecule inhibitors of ROCK-II, which promote smooth muscle relaxation, may be effective for the treatment of angina pectoris, 14 acute ischemic stroke, 15 hypertension, 16 glaucoma, 17, 18 and erectile dysfunction (ED). [19] [20] [21] Because it is a well-characterized enzyme, ROCK-II also serves as an excellent target for evaluating novel HTS assay technologies. 22, 23 In the research presented here, HTS assays were developed for ROCK-II inhibitors in both LK and TR-FRET formats. The assays were miniaturized and validated in 1536-well microplates and screened against small-molecule compound libraries. This article critically evaluates the performance, sensitivity, and economy of the LK and TR-FRET formats in light of the results from these efforts.
MATERIALS AND METHODS
Long-chain biotin S6 peptide. LCB-S6 (LCB-AKR-RRLSSLRA-NH 2 ) was synthesized in the TSRI peptide synthesis core facility.
6-His-tagged ROCK-II 1-543 cloning. The human ROCK-II gene, amino acids 1-543, was amplified in a 2-step PCR. Initially, cDNA was reverse transcribed (RETROscript First Strand Synthesis Kit for RT-PCR, Ambion, Foster City, CA) from human brain total RNA (BD Biosciences Clontech, Mountain View, CA) using oligo dT primers. In the first PCR reaction, a partial 1950-bp ROCK-II cDNA fragment was amplified as previously described. 12 Amino acids 1-543 of human ROCK-II were generated with a second PCR using Platinum PCR SuperMix High Fidelity (Invitrogen, Carlsbad, CA) (cycling conditions: 94 °C for 30 s, 65 °C for 30 s, 68 °C for 135 s, 30 cycles). Primers were 5′-TACTTCCAATC-CAATGCCATGAGCCGGCCCCCGC-3′ and 5′-TTATCCAC-TTCCAATGTTACAAATCTTCAAGTTGATCTTTTAAGC-3′. The resulting PCR product was subcloned into a ligationindependent modified pFastbac vector, 24 resulting in 6xHis epitope followed by a tobacco etch virus (TEV) cleavage site N-terminal to the start ATG of ROCK-II. Clone identity was confirmed by DNA sequencing.
Generation of recombinant baculovirus encoding 6-His-tagged ROCK-II 1-543. The 6-His-tagged ROCK-II fragment subcloned into pMCSG7 24 was transformed into Max Efficiency DH10Bac (Invitrogen). Transformants were plated onto LB agar plates containing 50 μg/mL kanamycin, 7 μg/mL gentamycin, 10 μg/mL tetracycline, 200 μg/mL X-gal, and 40 μg/mL isopropyl-beta-Dthiogalactopyranoside (IPTG). Colonies containing the recombinant His-ROCK-II bacmid were selected, based on blue-white screening, and streaked on a second set of plates. His-ROCK-II encoding bacmid DNA was purified from overnight bacterial cultures. Presence of His-ROCK-II within the bacmid DNA was verified by PCR. Sf 9 cells in a 6-cm dish (~60%-80% confluent) were transfected with 1 μg of His-ROCK-II bacmid DNA using 6 μL of Cellfectin (Invitrogen). Approximately 4 days posttransfection, the supernatant from transfected cells was harvested to obtain a P1 viral stock. Sf 9 cells were maintained in serum-free insect cell media (Expression Systems, Sacramento, CA) at 27 °C. Viral plaques were isolated 10 days posttransfection using P1 virus stock. Isolated plaques were amplified by reinfection of Sf 9 cells. A viral clone yielding high His-ROCK-II expression was identified by Western blot. This virus was amplified for an additional 3 cycles to generate a higher titer virus stock at 8.0 × 10 9 infectious viral particles/mL. Protein expression. Protein expression was optimized by measuring relative levels of protein expression by Western blot over a 4-day time course and using 4 differing multiplicities of infection (MOI) of 1, 2, 5, and 10. For optimization of protein expression and larger scale protein production, Sf 9 cells were cultured at 27 °C in spinner flasks (Fisher, Waltham, MA) at a density of 2.0 × 10 6 cells/mL. For large-scale protein production, Sf 9 cells were infected for 3 days using an MOI of 2. Sf9 insect cell pellets from 1 L of cells were lysed in a 50-mL lysis buffer (50 mM HEPES [pH 7], 100 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 1% protease inhibitor cocktail [P8465; Sigma-Aldrich, St. Louis, MO], 5 mM Tris[2-carboxyethyl]phosphine hydrochloride [TCEP], and 0.1% Triton X100) and cleared by centrifugation for 15 min, 20,000g, and 4 °C. The supernatant was loaded on a 1-mL Ni-affinity column (Hi-Trap fast flow, GE Healthcare, Piscataway, NJ). Nonspecific proteins were eluted at 40 mM imidazole, and ROCK-II was eluted at 250 mM imidazole in HEPES buffer described above. Loading of 3 μg of purified ROCK-II showed no visible contamination, as determined by Coomassie stain sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis (data not shown). The eluted protein was washed and concentrated in 50 mM HEPES (pH 7), 100 mM NaCl, 5 mM TCEP, and 1% protease inhibitor cocktail. Purified ROCK-II was aliquoted and frozen at -80 °C.
384-well format kinase assays.
All experiments were performed in 384-well low-volume microplates (Greiner, Monroe, NC). Chemicals were purchased from Sigma-Aldrich unless noted otherwise below.
TR-FRET assay. A 6-μL mixture of 1 μM S6 peptide (LCB-AKRRRLSSLRA-NH 2 , where LCB = long chain biotin) and 20 μM ATP in kinase buffer (50 mM HEPES, pH 7.3 [Invitrogen]; 10 mM MgCl 2 ; 0.1% bovine serum albumin [BSA]; 2 mM dithriothreitol [DTT]) was added to the wells using a FRD™ IB Workstation (Aurora Discovery, Carlsbad, CA). Then, 20 nL of 90% DMSO/10% water containing the compounds to be tested (or no compound, 70 nM of Y-27632, or 20 μM of Y-27632 for control wells) was dispensed using a 384-head offline Pintool system (GNF Systems, San Diego, CA). Reactions were initiated by addition of 6 μL of 0.5 nM ROCK-II (1-543) in kinase buffer. After 25 min at room temperature (RT), the reaction was stopped with a 8-μL mixture of 187.5 nM streptavidin XL665 (Cisbio, Gif-sur-Yvette, France) and 2.5 ng of custom Eu 3+ cryptate-labeled (Cisbio, Cryptate/Antibody 4.17) phospho S6 peptide antibody (#2211, Cell Signaling, Danvers, MA) in Quench buffer (31.25 mM HEPES, pH 7.5 [Invitrogen]; 312.5 mM KF; and 187.5 mM EDTA). After a 2-h incubation at RT, the plate was read on the Viewlux in TR-FRET mode.
LK assay. A 5-μL mixture of 20 μM S6 peptide (LCB-AKRRRLSSLRA-NH 2 ) and 20 μM ATP in kinase buffer (50 mM HEPES [pH 7.3], 10 mM MgCl 2 , 0.1% BSA, 2 mM DTT) was added to the wells using a FRD™ IB Workstation (Aurora Discovery). Then, 20 nL of 90% DMSO/10% water containing the compounds to be tested (or no compound for control wells) was dispensed using a 384-head offline Pintool system (GNF Systems). The reaction was started by addition of 5 μL of 8 nM ROCK-II (1-543) in kinase buffer (5 μL of kinase buffer for high wells). After 50 min at RT, the reaction was stopped by addition of 10 μL Kinase-Glo reagent, and the plate was read after a 10-min incubation time at RT on the Viewlux in luminescence mode.
1536-well format kinase assays
The reagents, suppliers, and equipment used for 1536-well assay development and HTS efforts were identical to those used in the 384-well format unless noted otherwise below. All experiments were performed in the 1536-well source and donor plates, and a 1536-pin tool was used for compound transfer. The final protocols are described below; discussion of assay optimization of biochemical parameters is addressed in the Results and Discussion section. 
LK and TR-FRET assay validation and HTS campaigns (1536-well format). Assay validation experiments and HTS
campaigns were executed on a GNF/Kalypsys ultra-HTS (uHTS) platform, using integrated liquid handlers, incubators, and a multipurpose plate reader (PerkinElmer). Assay protocols were identical to those described above for 1536-well assay development. National Institutes of Health (NIH) and institutional screening files were selected for testing as appropriate. Validation experiments were performed with a small compound library (n = 1280) with known pharmacologic activity (cat. L01280, Sigma). Assay parameters were identical between the validation and HTS campaigns. Test compounds were present at 6 μM in assay.
For TR-FRET assays, raw well data were first prepared by calculating the quotient of 617-and 671-nm fluorescence units and multiplying the result by 10,000. For both formats, background signal (i.e., signal from wells containing all reagents except enzyme) was subtracted from test compound and control well values prior to inhibition calculations. To calculate percent inhibition, the test compound well signal was divided by the median signal from the 100% inhibition positive control wells (i.e., wells containing Y-27632) and multiplied by 100.
A mathematical algorithm was used to determine nominally inhibitory compounds in the primary screen. 25 Two values were calculated: (1) the average percent inhibition of all compounds tested and (2) 3 times their standard deviation. The sum of these 2 values was used as a cutoff parameter (i.e., any compound that exhibited greater percent inhibition than the cutoff parameter was declared active).
Cheminformatics.
To determine what compounds were shared between the 60K and 600K screening files, chemical structures in the NIH Molecular Libraries Small Molecule Repository (MLSMR) and Scripps institutional screening libraries were standardized applying in-house business rules as implemented using Cheshire in the structure registration system (ChemBio AE, Elsevier MDL; http://www.mdl.com/products/experiment/chembio_ ae/index.jsp). Salt forms were removed based on an institutional collection of addend structures. Tautomers were canonicalized and canonical smiles generated using a method derived from the Daylight canonicalization algorithm as implemented in Pipeline Pilot (Scitegic, http://www.scitegic.com/). Based on these standardizations, 24,779 structures appeared in both collections. Among these, active structural classes were identified for both the TR-FRET and LK readouts (primary normalized percent inhibition) by recursive partitioning and simulated annealing (RPSA) analysis and hierarchical agglomerative clustering using Leadscope structural keys (Leadscope, http://www.leadscope.com/).
To determine format-specific artifacts, additional assay data were retrieved from the NIH's National Center for Biotechnology Information (NCBI) PubChem database (http://pubchem.ncbi.nlm .nih.gov/), a publicly accessible repository for results of HTS experiments performed under the auspices of the NIH's Molecular Library Screening Center Network (MLSCN). In this database, assays are identified uniquely by Assay ID (AID). TR-FRETbased HTS results were compared to those in the PubChem database, specifically those dealing with spectroscopic profiling of the compounds themselves (AID = 587-584) as well as various inhouse TR-FRET assay data. The results of the LK-based HTS campaign (AID = 604, 644) were compared to a luciferase profiling assay (AID = 411) and various other luciferase-based assay data that reside in PubChem.
Frequency distribution analysis. This was performed using GraphPad Prism ® version 4.03 suite of programs. Inhibition values were binned in 1% wide bins and plotted as number of compounds per bin versus inhibition (expressed as percent). Concordance of inhibition distribution to a normal (bellshaped) distribution was assessed using nonlinear regression analysis for Gaussian distribution.
RESULTS AND DISCUSSION
Experimental design of the TR-FRET and LK assays. Initial studies involved the independent optimization and miniaturization of the TR-FRET and LK formats. A primary goal of this research was to ensure that the pharmacology of the assays agreed with the previously established enzymology of ROCK-II (1-543), where K M values for the S6 ribosomal peptide (LCB-AKRRRLSSLRA-NH2) and ATP were determined to be 0.9 μM and 20 μM, respectively, in a radiometric assay. 26 Building on this research, the S6 substrate was also employed for the TR-FRET and LK assay development. To allow for screening of both substrate-and ATP-binding inhibitors, initial attempts were made to run the kinase assays at ½ K M for both ATP (10 μM) and S6 peptide substrate (0.5 μM).
Because the TR-FRET assay requires the binding of the FRET acceptor to a biotinylated substrate, the biotinylated (LCB) form of the S6 substrate was chosen for both the TR-FRET and LK formats. It is important to note that LCB is unnecessary for signal generation in the LK format. However, use of a single substrate for both formats aided not only the comparison the LK and TR-FRET assay results but also comparison of these results with those previously obtained via capture of the 33 P-phospho product on filter membranes. 23 In similar fashion, preliminary attempts were made to accord as many biochemical parameters (e.g., reagent concentrations, buffer species, etc.) as possible between the 2 formats. As described in detail below, if an assay's sensitivity, enzymology, or economy suffered from attempts to accord assay parameters, protocols were revised as appropriate to generate robust, miniaturized HTS-compatible assays.
As a final consideration in the LK assay design, special attention was paid to the relative ATP and substrate concentrations. In contrast to the TR-FRET assay, which measures the creation of the phosphorylated substrate, the chemiluminescent luciferase assay measures unconverted ATP remaining after the kinase reaction has completed. Discussed in detail elsewhere, this feature may be problematic in creating an effective LKformat HTS campaign for certain kinase systems; others have suggested that the LK format is most suitable for kinases where the K M for ATP is lower than that for the kinase cosubstrate. 12 In the case of ROCK-II, running the LK assay at the K M values for ATP and peptide would mean that the S6 substrate concentration would be 20-fold lower than the ATP concentration, undermining the sensitivity of the LK assay. In light of ROCK-II pharmacology and the goals of the HTS effort, it was decided that a saturating concentration of S6 peptide (10 μM) and ½ K M concentration of ATP (10 μM) be used. In theory, running the assay at saturating S6 peptide concentration would bias a LKformat HTS campaign to the discovery of ATP competitive inhibitors only, but this potential disadvantage was tempered by the fact that the assay would be sensitive to any inhibitor that significantly decreased the consumption of ATP.
Development of the 1536-well format assays. For both the TR-FRET and LK assays, the biochemical parameters of the 384-well experiments, described in detail in the Materials and Methods section, were similar to those of the 1536-well format experiments. The following discussion is focused on the 1536well format assay results.
Optimization of the 1536-well format TR-FRET assay.
Preliminary TR-FRET assay development efforts focused on determining the kinetics of the enzymatic reaction. The titration of the ROCK-II enzyme at a variety of concentrations proved the reaction gave robust TR-FRET responses (Fig. 1) . In addition, a 10-point dose-response curve of the inhibitor Y-27632 was employed as the positive control for each time point to determine the effect of incubation time on the IC 50 value. As expected, it was found that longer incubation times of enzyme with substrate gave correspondingly less potent IC 50 values (data not shown); to balance assay sensitivity with signal strength, a concentration of 0.25 nM of enzyme and an incubation time of 30 min were chosen for further experiments. At this concentration and incubation time, the kinetic response was found linear, with a correlation coefficient of R 2 = 0.9946.
Using the final enzymatic reaction conditions described above, the relative concentrations of the FRET donor/acceptor pair and their incubation time with the phosphorylated substrate were also optimized. Matrix experiments that varied the concentrations of the 2 species relative to each other were conducted (Fig. 2) . As defined by the Z′ factor, 27 it was found that a final concentration of 2.5 ng/well of anti-phospho S6 peptide and 75 nM of acceptor fluorophore resulted in the most robust TR-FRET signal. As a final step to TR-FRET assay development, the incubation time of the donor/acceptor/phosphorylated product complex was also optimized. It was found that a 2-h incubation time gave an acceptable Z′ factor without extending the total duration of the assay unnecessarily. Final reaction conditions for the TR-FRET assay are summarized in Table 1 .
Optimization of the 1536-well LK ROCK-II assay. The luciferase detection buffer is sold as a kit, where optimal luciferin/luciferase concentrations are premixed at proprietary concentrations. Therefore, assay optimization focused on adaptation of ROCK-II enzymology to the format. Enzyme titration experiments produced consistent, predictable kinetics ( Fig. 1) ; however, it was found that in addition to saturating concentrations of substrate (described in detail above), significantly higher concentrations of ROCK-II and longer kinase reaction times were necessary to generate sufficient luminescence signal. Based on these results, a concentration of 4 nM of enzyme and a kinase reaction incubation time of 100 min were chosen for further experiments.
Validation of LK and TR-FRET assays. The pharmacologic validation of both assays was done with 2 well-characterized ROCK-II inhibitors, fasudil and Y-27632, 28 as well as the nonspecific kinase inhibitor staurosporine. All compounds were titrated in 10point dilutions sufficient to calculate IC 50 values (Fig. 3) . For all compounds tested, graded dose-response curves were observed. Inhibitor IC 50 values were similar between the TR-FRET and LK formats and also compared favorably with those found in literature. 23, 28 It should be noted that the 22,700-nM IC 50 reported in Table 2 of Turner et al 23 To gauge the ability of the LK and TR-FRET assays at identifying different known kinase inhibitors, a small library of pharmacologically active compounds was screened in the 1536-well format. All compounds were tested once at a 6-μM final concentration, mimicking final test concentrations of the HTS campaign. The results of this effort showed that the assays were sensitive to several known kinase inhibitors, including Y-27632, which was present within the library. The inhibition values between the formats also compared favorably, with R 2 of 0.636 (n = 1280 data not shown).
As a final test of assay readiness for HTS, all reagents were tested for 8-h stability at room temperature. For the TR-FRET format, some loss in assay signal-to-basal (S/B) ratio was observed (S/B t = 0 h = 2.54 ± 0.10, S/B t = 8 h = 2.41 ± 0.11, n = 16), but this loss did not appear to significantly affect the assay window (Z′ t = 0 h = 0.79, Z′ t = 8 h = 0.79, n = 16). Similarly, the LK assay appeared to lose a significant portion of its signal over time (S/B t = 0 h = 2.02 ± 0.05, S/B t = 8 h = 1.68 ± 0.03, n = 16), but the assay window remained robust (Z′ t = 0 h = 0.82, S/B t = 8 h = 0.76, n = 16). From the results of these experiments, it was decided that both assays could be run in batch mode at room temperature for the HTS campaign.
HTS campaign results for TR-FRET and LK formats.
To diversify the discovery of novel ROCK-II inhibitors, 2 separate libraries were screened in the 1536-well format. For the LK HTS campaign, a publicly available library was screened under the auspices of the MLSCN initiative sponsored by the NIH. 29 For the TR-FRET HTS campaign, a larger institutional library consisting of ~600,000 substances was screened. In this campaign, compounds were tested in daily batches of ~100 plates; in the case of the LK HTS campaign, all ~60,000 compounds in the NIH screening file were tested in a single batch. It is important to note that despite differing incubation times, both HTS assay formats had the same number of protocol steps, and identical volumes were dispensed during each step ( Table 1) . For these reasons, both HTS campaigns ran at a steady-state throughput of 11 plates/h. As shown in Figure 4A , both the TR-FRET and LK HTS campaigns yielded consistent plate-to-plate results. In the case of the TR-FRET assay, the average Z′ factor of all plates tested was 0.72 ± 0.05, with an average plate S/B of 2.59 ± 0.25 (n = 474 plates). Despite the lower average plate S/B for the LK campaign (2.03 ± 0.1), it appeared slightly more robust, with an average plate Z′ factor of 0.84 ± 0.03 (n = 48).
Calculated 3SD + Ave for the LK primary HTS campaign was 18.22%, but for the purposes of comparing results obtained by TR-FRET and LK assay formats, we are using the same 25.22% inhibition cutoff obtained from the TR-FRET primary HTS campaign. The primary HTS campaign of the Scripps institutional library in TR-FRET assay format yielded 3758 hits using 25.22% inhibition as a hit cutoff parameter (3SD + Ave rule; see description in Materials and Methods), which constituted a 0.63% hit rate. When retested in a TR-FRET confirmation assay, 1731 of these 3758 compounds had confirmed their activity in the ROCK-II TR-FRET assay, which constituted a 46% confirmation rate and a 0.29% total hit rate ( Table 2) . The confirmed hits in the TR-FRET assay belonged to 132 distinct structural classes ( Table 2) .
The primary HTS campaign of the MLSCN compound library in the LK assay format yielded 134 hits using the same 25.22% inhibition cutoff as the TR-FRET assay, which constituted a 0.22% hit rate. The higher hit rate of the TR-FRET primary HTS assay (0.65% vs. 0.22% in the LK primary assay) can be attributed to the higher scatter observed in the TR-FRET primary screen data, evidenced by lower Z′ factor values (see above) and higher measured S/B standard deviations (S/B: 2.59 ± 0.25 vs. 2.03 ± 0.1 for LK primary screen) (Fig. 4A) .
When the 134 LK format hits were retested in the confirmation assay, 120 had confirmed their activity in the LK assay, which constituted an 89.5% confirmation rate and a 0.20% total hit rate ( Table 2 ). The confirmed hits of the LK assay belonged to 22 distinct structural classes ( Table 2 ). In both the TR-FRET and the LK assay, compounds were tested once in the primary screen and in triplicate in the confirmation assay at a final nominal concentration of 6 μM.
Primary HTS assay frequency distribution analysis. Cheminformatic analysis of our ~600,000 (600K) compound institutional and ~60,000 (60K) compound MLSCN screening files yielded 24,779 (25K) overlapping structures (i.e., identical compounds found in both screening files). As a first step in the comparison of the TR-FRET and LK campaign results, a statistical analysis was conducted on this 25K overlapping set of compounds as well as on the separate screening files (60K and 600K). First, inhibition distribution analysis was performed using results from the 600K (TR-FRET) and 60K (LK) primary screening efforts as well as the overlapping 25K subset results, which had primary HTS results in both the TR-FRET and LK format (Fig.  4B) . The 60K LK primary assay had a mean inhibition value of 2.76% ± 3.9% (R 2 = 0.987), and the 600K TR-FRET primary assay showed 0.012% ± 5.93% (R 2 = 0.999). The same analysis on the 25K overlapping compounds yielded mean inhibition values of 2.79% ± 3.96% (R 2 = 0.992) and 0.07% ± 5.71% (R 2 = 0.998), respectively, for LK and TR-FRET.
Overall, the results obtained using the TR-FRET assay format exhibited a slightly better fit to the Gaussian distribution when compared to the LK format, as evidenced by R 2 values. As illustrated in Figure 4B , the results for the inhibition distribution analysis from the 25K subset were comparable to those obtained from the full libraries by corresponding assay formats. This observation led us to believe that the 25K subset of compounds that were analyzed by both assay formats was a good representation of the diversity of the corresponding libraries and therefore could be used to compare the results and performance of the LK and TR-FRET HTS campaigns.
Comparison of HTS campaign results for TR-FRET and LK
formats based on the 25K compound subset. The first step in comparing the results of the LK and TR-FRET formats was to select the hits from the overlapping 25K primary screening data. Using the 25.22% inhibition hit cutoff parameter, the primary TR-FRET HTS campaign of the overlapping 25K set yielded 108 hits, which constituted a 0.44% primary hit rate ( Table 3 ). In a similar analysis, the primary HTS campaign of an overlapping 25K set in the LK format yielded 49 hits using the same 25.22% inhibition cutoff, which constituted a 0.2% primary hit rate ( Table 3) . Figure 5A illustrates the correlation of the 25K primary assay results produced by LK and TR-FRET assay formats. A general correlation exists, but there were several obvious outliers: 11 by LK and 64 by TR-FRET. Because the majority of these compounds did not confirm activity, they were declared "false positives"-that is, attributed to a campaign-specific artifact (e.g., dust or lint in a well)-and were not considered for the further analysis described below.
When the 108 TR-FRET hits were cherry-picked and retested in triplicate in the TR-FRET format, 41 compounds confirmed their activity (i.e., had inhibition values >25.22%), which constituted a 38% confirmation rate and a 0.17% total hit rate for the entire TR-FRET campaign ( Table 3 ). In a similar process, 37 of 49 LK format hits confirmed their activity when retested in triplicate in the LK format, constituting a 76% confirmation rate and a 0.15% total hit rate for the 25K LK campaign ( Table 3) .
Cheminformatic analysis of compounds that confirmed activity in the different formats. A set of analyses was performed to characterize the 44 compounds that confirmed activity in either format. In the case of the TR-FRET assay, the average Z′ factor of all plates tested was 0.72 ± 0.05, with an average plate S/B of 2.59 ± 0.25 (n = 474 plates); for the LK campaign, average plate S/B was 2.03 ± 0.1, with an average plate Z′ factor of 0.84 ± 0.03 (n = 48). (B) Frequency distribution histograms based on results of LK and TR-FRET assays of 600K, 60K, and 25K libraries. Bold-punctured outline represents the best fit to the Gaussian distribution model. The 60K LK primary assay had a mean inhibition value of 2.76% ± 3.9% (R 2 = 0.987), and the 600K TR-FRET primary assay showed 0.012% ± 5.93% (R 2 = 0.999). The same analysis performed on 25K overlapping compounds yielded mean inhibition values of 2.79% ± 3.96% (R 2 = 0.992) and 0.07% ± 5.71% (R 2 = 0.998) for LK and TR-FRET, respectively. From this set, 34 compounds (i.e., 77% of the total) were active in both formats. To better understand the nature of the format-specific hits, separate cluster analyses were performed on confirmed actives of each assay format. These results revealed that there were 12 clusters (i.e., compounds sharing similar structural features) with 2 or more members in the entire set of actives ( Table 3) . Of this total, 11 clusters were identical between the formats, accounting for 27 of the 44 compounds total. The remaining cluster, containing 2 members, belonged to the TR-FRET format. Closer analysis of this cluster revealed that one of its members confirmed activity only in the TR-FRET format, whereas the other cluster member appeared as a "singleton" (i.e., confirmed its activity but did not cluster) in the LK format. In addition, it was found that a TR-FRET cluster (n = 4) had only 3 members in its corresponding LK format cluster. Of the remaining 15 singletons, 7 were active in both assay formats, whereas 3 compounds were active only in the LK format and 5 confirmed active only in the TR-FRET format.
When the 10 format-specific confirmed hits are removed from the 44-compound data set, the resulting inhibition value correlation yields, as determined by linear regression, a line with a slope of 0.74 and an R 2 = 0.86 (n = 34) ( Fig. 5B) . This correlation of the retest results together with similar total hit rates (0.17% for TR-FRET and 0.15% for LK) indicated a comparable performance of the 2 different assay technologies. The slope of the best-fit line (m = 0.7), although close to unity, would suggest that the LK format is slightly more sensitive to the detection of ROCK-II inhibitors than the TR-FRET assay; however, the cluster analyses suggested that the TR-FRET assay was able to detect a greater number of structurally related compounds than the LK format. A further analysis was performed to investigate this observation.
Analysis of the TR-FRET format-specific hits. As mentioned above, 2 of the 7 format-specific TR-FRET actives belonged to TR-FRET clusters with members that were identical to those in the LK confirmed actives. Closer inspection of the LK format primary HTS campaign data revealed that 2 of these compounds had modest activity in the LK primary HTS campaign, but their inhibition values (22.1% and 22.2%) were slightly less than the hit cutoff of 25.22% and could have been otherwise counted as hits by lowering the threshold. In a similar manner, 2 of the TR-FRET format singletons (with 26.6% and 26.2% inhibition) were modestly potent in the LK format (24.5% inhibition, 23.28% inhibition), again missing the prescribed hit cutoff. Of the remaining 3 compounds, 2 compounds were identified as biotin analogs and therefore a TR-FRET-specific artifact. These compounds would compete with biotin-labeled substrate for streptavidin-XL binding, preventing FRET and appearing as pseudo-inhibitors. The last compound was found to be active in spectroscopic profiling assays performed by the NIH Chemical Genomics Center (NCGC) (http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=589), exhibiting fluorescence spectra characteristics similar to those of the fluorophores used in the TR-FRET assay format.
Analysis of the LK format-specific hits. We also analyzed the 3 compounds confirmed only by LK assay in a process similar to that used for the TR-FRET-specific actives. Two of the 3 compounds showed similar inhibition values in both LK (29.0% and 32.4%) and TR-FRET (24.2% and 21.7%) primary assays. However, these 2 compounds were not cherry-picked for the TR-FRET confirmation assay because their inhibition values were just below the hit cutoff setting of 25.22%. The third compound yielded a 27.2% inhibition in the primary LK assay and a -19.3% inhibition in the TR-FRET assay. It can be hypothesized that this latter compound enhances fluorescence or luminescence, which would constitute artifact in the LK format or the TR-FRET format. and 7 by TR-FRET only). Of the compounds identified by only 1 detection format, 5 compounds (3 in TR-FRET and 2 in LK format) were slightly below the primary HTS hit cutoffs. From these data, it may be concluded that the TR-FRET assay is more sensitive than the LK assay; however, the closeness of the inhibition values for the compounds in question would suggest that the discrepancy is more likely due to the scatter of data points close to the hit cutoff rather than systemic assay limitations. It follows from this analysis that both assay formats allowed a relatively low amount of false negatives. In addition, the TR-FRET format appeared somewhat more susceptible to format-specific artifact. Specifically, there were 3 compounds found in the TR-FRET confirmation assay with activities that could be attributed to either biotin-like structure or high autofluorescence, which would appear at TR-FRET-specific hits. In contrast, the LK format appeared to have only 1 formatspecific artifact, and this was attributed to the compound's hypothetical luminescence/fluorescence-enhancing properties. However, this cannot be confirmed without further experimentation. Overall, this relatively small amount of artifact (approximately 1 artifact per 10,000 compounds screened) suggests that either format is suitable for HTS of a random screening file.
Economic analysis of TR-FRET and LK assay formats for ROCK-II. Based on publicly available price lists, the cost/well of assay reagents for the TR-FRET and LK assays was calculated to be 2.9¢/well and 2.5¢/well, respectively. The bulk of the costs for the TR-FRET assay were the antibody and FRET acceptor preparations, which came to approximately 93% of the total. In contrast, the luciferase preparation was only 12% of the total cost per well for the LK assay. This economic advantage was offset by a high concentration of enzyme necessary to generate sufficient signal, which represented 85% of the total assay cost.
CONCLUSION
The results presented here describe the application of 1 well-tested assay methodology for kinases, a time-resolved fluorescence resonance energy transfer format (TR-FRET), [30] [31] [32] and another less characterized orthogonal luminescence readout, a luciferase-coupled kinase format (LK). 10 To enable the identification of ROCK-II inhibitors, we developed both formats as 1536-well HTS assays. Robust HTS campaigns were successfully completed for both formats using screening files consisting of 600K (for the TR-FRET campaign) and 60K (for the LK campaign) members.
The existence of a set of 25,000 (25K) compounds shared between the 2 screening files facilitated the comparison of the results from the LK and TR-FRET HTS campaigns. Both assays exhibited a similar concordance to a normal (Gaussian) model of primary HTS inhibition distribution ( Fig. 4B) and comparable total hit rate ( Table 3) . Among the 44 total compounds that confirmed activity, most (~77%) were active in both formats. Of those 10 compounds that confirmed activity in only 1 format, the majority had inhibition values only slightly below the primary HTS nominal hit cutoff. Of the remainder, 3 TR-FRET and 1 LK compounds were attributed to formatspecific artifact.
In summary, these results suggest that both assays are equally suited to the discovery of kinase inhibitors via HTS of large compound files without being prone to overwhelming amounts of artifacts. In fact, the results of the validation experiments and the HTS campaigns show that both formats were able to detect known and unknown kinase inhibitors with comparable sensitivity. Although no practical evidence was found in this study, one must consider that the saturating concentrations of substrate necessary to generate signal in the LK assay may make it less sensitive to substrate-competitive inhibitors. It is important to note that (1) saturating substrate conditions may not be necessary for other kinase systems, and (2) despite the high concentrations of substrate necessary to generate sufficient signal, the LK assay remains an economical alternative to TR-FRET assays.
